Coined by industry as the only meeting of its kind and uniquely positioned to share fresh ideas and assess viable approaches to your most pressing preclinical, translational, and clinical bottlenecks, the 5th Inner Ear Disorders Summit returns as a forum to benchmark learnings from past failures, reignite momentum and develop investment into the audiology therapeutic landscape.
With pioneering insights from Regeneron, Biogen, Acousia, Rinri, Ting Therapeutics, Lineage Cell Therapeutics, and more, this will be an opportunity to:
- Advance preclinical models to recapitulate complex human inner ear pathophysiology
- Deepen knowledge of molecular and genetic pathways with our deep dive drug delivery workshops
- Evaluate clinical progress in gene therapy for restored hearing and decipher the journey to success in Phase III populations
- Overcome translational challenges of bringing advanced therapies, including small molecule and cell-based approaches, to the clinic
- Uncover opportunities for drug-device combinations to enable precise drug delivery and enhance the hearing preservation capabilities of cochlear implants
- Hear large pharma and investor perspectives on what must be demonstrated to de-risk business opportunities within the hearing disorders space.
Join this forum of biotech innovators, pharma stakeholders, investors and leading academics in a collaborative atmosphere to advance audiology R&D through cell, gene and small molecule therapies to transform the treatment of hearing loss.
The 5th Inner Ear Disorders Therapeutics Summit 2025 is the industry's must-attend event tackling challenges in hearing loss treatment R&D.
For the full Event Guide and booking details, see:
https://inner-ear-disorders-therapeutics.com
Book now for final early bird savings of up to $300.
ENT & Audiology News readers are entitled to a 10% discount with the code: ENT10
